An open label SLV308 safety extension to study S308.3.001 in early PD patients. - An extension of the Rembrandt study
- Conditions
- Parkinson's Disease Early Stage
- Registration Number
- EUCTR2006-000858-45-FI
- Lead Sponsor
- Solvay Pharmaceuticals
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Subjects who have signed informed consent for participation in the extension study.
- Subjects who have completed the S308.3.001 trial.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- Subjects with medically relevant abnormal findings (ECG, physical examination, AEs) at end of the maintenance phase (Visit M6, Week 24) of study S308.3.001.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method